History of alternative preventive therapies for type 1 diabetes mellitus
Open Access
- 24 February 2025
- journal article
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 32 (1) , 87-98
Abstract
Background. Type 1 diabetes mellitus refers to one of the most prevalent chronic diseases. In recent years, a steady growth in this nosology has been registered in the Russian Federation, as well as globally, particularly among children and adolescents. Consequently, the number of children and adolescents classified as disabled by type 1 diabetes mellitus is also rising, prompting the global medical community to focus on mitigating these issues. The primary treatment for type 1 diabetes mellitus involves insulin replacement therapy combined with self-monitoring of blood glucose levels. Currently, insulin pumps and devices for continuous glucose monitoring have been developed and implemented in clinical practice, enhancing the effectiveness of type 1 diabetes mellitus treatment and significantly improving the quality and expectation of lives. However, even hybrid closed-loop systems (a combination of continuous subcutaneous insulin infusion and continuous glucose monitoring) fail to achieve physiological regulation of blood glucose levels and to completely eliminate the risk of long-term complications.Objectives. To explore the history of alternative preventive therapeutic methods for type 1 diabetes mellitus based on data from both Russian and international research literature.Methods. A comparative analysis of literature from both Russian and international authors addressing the issues of therapy and prevention of type 1 diabetes mellitus was conducted using the scientometric database eLibrary. ru and the biomedical search engine PubMed.Results. The search for alternative therapeutic methods that can prevent or delay the onset of the diabetes remains relevant. These therapeutic methods can be conditionally divided into conservative and surgical approaches, primarily aimed at protecting pancreatic β-cells from immune-mediated destruction. Notable immunotherapeutic agents include antiproliferative agents, systemic immunomodulators, T-cell inhibitors, monoclonal antibodies, autoantigens, various types of stem cells, dendritic cells, and microbiota therapy.Conclusion. The paper presents several experimental methods of preventive therapy for type 1 diabetes mellitus and the results of studies conducted in this area, describes the proposed mechanisms for establishing immunological tolerance. A brief overview of completed and ongoing clinical trials is provided.Keywords
This publication has 61 references indexed in Scilit:
- Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)Acta Diabetologica, 2022
- Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 DiabetesJAMA, 2018
- Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 DiabetesJAMA, 2017
- Emerging Concepts on Disease-Modifying Therapies in Type 1 DiabetesCurrent Diabetes Reports, 2017
- T‐lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossoverDiabetes/Metabolism Research and Reviews, 2016
- Generation of Functional Human Pancreatic β Cells In VitroCell, 2014
- Effect of Cholecalciferol as Adjunctive Therapy With Insulin on Protective Immunologic Profile and Decline of Residual β-Cell Function in New-Onset Type 1 Diabetes MellitusArchives of Pediatrics & Adolescent Medicine, 2012
- Insulin treatment in IA-2A-positive relatives of type 1 diabetic patientsDiabetes & Metabolism, 2009
- Early Infant Feeding and Risk of Developing Type 1 Diabetes–Associated AutoantibodiesJAMA, 2003
- Cyclosporine Delays but does not Prevent Clinical Onset in Glucose Intolerant Pre-type 1 Diabetic ChildrenJournal of Autoimmunity, 1996